Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Cash from Investing Activities (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Cash from Investing Activities for 9 consecutive years, with $20.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 87.94% to $20.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $255.3 million, a 387.62% increase, with the full-year FY2025 number at $255.3 million, up 387.62% from a year prior.
  • Cash from Investing Activities was $20.8 million for Q4 2025 at Denali Therapeutics, down from $57.8 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $172.2 million in Q4 2024 to a low of -$453.2 million in Q1 2024.
  • A 5-year average of $12.6 million and a median of $39.3 million in 2025 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: surged 554.45% in 2023, then tumbled 388.8% in 2024.
  • Denali Therapeutics' Cash from Investing Activities stood at -$40.8 million in 2021, then crashed by 213.03% to -$127.6 million in 2022, then surged by 157.27% to $73.0 million in 2023, then soared by 135.75% to $172.2 million in 2024, then plummeted by 87.94% to $20.8 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Cash from Investing Activities are $20.8 million (Q4 2025), $57.8 million (Q3 2025), and $157.9 million (Q2 2025).